FDA Starts Safety Review of Autoimmune Disorder Drugs
Reports of increased cancer risk among young users of TNF blockers prompts action
Posted June 4, 2008
The maker of Cimzia, UCB Inc., must conduct a study looking at the long-term risks of this drug. That study will begin in 2009, and will take about a decade to complete.
In the meantime, the FDA has asked health-care professionals to weigh the possible risks against the benefits when prescribing TNF blockers.
More information
Read about TNF blockers U.S. Food and Drug Administration.
advertisement
